Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Vasc Med ; 25(1): 3-12, 2020 02.
Article in English | MEDLINE | ID: mdl-31512991

ABSTRACT

Evidence suggests that statin therapy in patients with peripheral artery disease (PAD) is beneficial yet use remains suboptimal. We examined trends in statin use, intensity, and discontinuation among adults aged ⩾ 40 years with incident severe PAD and a subset with critical limb ischemia (CLI) between 2002 and 2015 within an integrated healthcare delivery system. Discontinuation of statin therapy was defined as the first 90-day gap in treatment within 1 year following PAD diagnosis. We identified 11,059 patients with incident severe PAD: 31.1% (n = 3442) with CLI and 68.9% (n = 7617) without CLI. Mean (SD) age was 68.6 (11.3) years, 60.5% were male, 54.2% white, 23.2% Hispanic, and 16.2% black. Statin use in the year before diagnosis increased from 50.4% in 2002 to 66.0% in 2015 (CLI: 43.7% to 68.0%; without CLI: 53.1% to 64.2%, respectively). The proportion of patients on high-intensity statins increased from 7.3% in 2002 to 41.9% in 2015 (CLI: 7.2% to 39.4%; without CLI: 7.4% to 44.2%, respectively). Of the 40.5% (n = 4481) who were not on a statin in the year before diagnosis, 13.5% (n = 607) newly initiated therapy within 1 month (CLI: 10.1% (n = 150); without CLI: 15.3% (n = 457)). Following diagnosis, 12.5% (n = 660) discontinued statin therapy within 1 year (CLI: 15.5% (n = 202); without CLI: 11.5% (n = 458)). Although use of statins increased from 2002 to 2015, a substantial proportion of the overall PAD and CLI subpopulation remained untreated with statins, representing a significant treatment gap in a population at high risk for cardiovascular events and adverse limb outcomes.


Subject(s)
Delivery of Health Care, Integrated/trends , Dyslipidemias/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Ischemia/drug therapy , Peripheral Arterial Disease/drug therapy , Practice Patterns, Physicians'/trends , Adult , Aged , Aged, 80 and over , California/epidemiology , Critical Illness , Drug Utilization/trends , Dyslipidemias/diagnosis , Dyslipidemias/epidemiology , Female , Guideline Adherence/trends , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Incidence , Ischemia/diagnosis , Ischemia/epidemiology , Male , Middle Aged , Peripheral Arterial Disease/diagnosis , Peripheral Arterial Disease/epidemiology , Practice Guidelines as Topic , Retrospective Studies , Risk Factors , Severity of Illness Index , Time Factors , Treatment Outcome
2.
Ther Adv Cardiovasc Dis ; 7(5): 260-73, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24132556

ABSTRACT

The first case of noncompaction was described in 1932 after an autopsy performed on a newborn infant with aortic atresia/coronary-ventricular fistula. Isolated noncompaction cardiomyopathy was first described in 1984. A review on selected/relevant medical literature was conducted using Pubmed from 1984 to 2013 and the pathogenesis, clinical features, and management are discussed. Left ventricular noncompaction (LVNC) is a relatively rare congenital condition that results from arrest of the normal compaction process of the myocardium during fetal development. LVNC shows variability in its genetic pattern, pathophysiologic findings, and clinical presentations. The genetic heterogeneity, phenotypical overlap, and variety in clinical presentation raised the suspicion that LVNC might just be a morphological variant of other cardiomyopathies, but the American Heart Association classifies LVNC as a primary genetic cardiomyopathy. The familiar type is common and follows a X-linked, autosomal-dominant, or mitochondrial-inheritance pattern (in children). LVNC can occur in isolation or coexist with other cardiac and/or systemic anomalies. The clinical presentations are variable ranging from asymptomatic patients to patients who develop ventricular arrhythmias, thromboembolism, heart failure, and sudden cardiac death. Increased awareness over the last 25 years and improvements in technology have increased the identification of this illness and improved the clinical outcome and prognosis. LVNC is commonly diagnosed by echocardiography. Other useful diagnostic techniques for LVNC include cardiac magnetic resonance imaging, computerized tomography, and left ventriculography. Management is symptom based and patients with symptoms have a poorer prognosis. LVNC is a genetically heterogeneous disorder which can be associated with other anomalies. Making the correct diagnosis is important because of the possible associations and the need for long-term management and screening of living relatives.


Subject(s)
Echocardiography , Isolated Noncompaction of the Ventricular Myocardium/physiopathology , Animals , Child , Death, Sudden, Cardiac/etiology , Humans , Infant, Newborn , Isolated Noncompaction of the Ventricular Myocardium/diagnosis , Isolated Noncompaction of the Ventricular Myocardium/therapy , Magnetic Resonance Imaging , Tomography, X-Ray Computed
3.
J Relig Health ; 51(4): 1124-36, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23304705

ABSTRACT

Heart failure (HF) is a chronic progressive disease with marked morbidity and mortality. Patients enduring this condition suffer from fluctuations in symptom burden such as fatigue, shortness of breath, chest pain, sexual dysfunction, dramatic changes in body image and depression. As physicians, we often ask patients to trust in our ability to ameliorate their symptoms, but oftentimes we do not hold all of the answers, and our best efforts are only modestly effective. The suffering endured by these individuals and their families may even call into question one's faith in a higher power and portends to significant spiritual struggle. In the face of incurable and chronic physical conditions, it seems logical that patients would seek alternative or ancillary methods, notably spiritual ones, to improve their ability to deal with their condition. Although difficult to study, spirituality has been evaluated and deemed to have a beneficial effect on multiple measures including global quality of life, depression and medical compliance in the treatment of patients with HF. The model of HF treatment incorporates a multidisciplinary approach. This should involve coordination between primary care, cardiology, palliative care, nursing, patients and, importantly, individuals providing psychosocial as well as spiritual support. This review intends to outline the current understanding and necessity of spirituality's influence on those suffering from HF.


Subject(s)
Heart Failure/rehabilitation , Religion and Medicine , Spirituality , Chronic Disease , Heart Failure/psychology , Heart Transplantation , Humans , Palliative Care , Patient Compliance , Quality of Life , Religion , Self Care
4.
J Cardiovasc Pharmacol Ther ; 16(1): 14-23, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21097668

ABSTRACT

Heart failure (HF) is a complex progressive multisystem disease state with significant morbidity and mortality, which is not solely defined by pathology of the cardiovascular system but also is influenced by neurohormonal regulatory adjustments, peripheral cytokines, as well as hormonal and musculoskeletal dysfunction. Recent attention to the catabolic state found in patients with chronic heart failure has sparked interest in new potential targets for medical therapy. In particular, as many as 26% to 37% of men affected with HF have been found to be testosterone deficient. The severity of androgen deficiency has been shown to correlate with symptoms, functional class, and prognosis in patients with heart failure. Testosterone supplementation has been an accepted therapy in hypogonadal men with fatigue, muscle wasting, and sexual dysfunction for some time. Patients with severe HF show a similar constellation of symptoms and hypothetically would benefit from androgen replacement. Recent clinical studies have confirmed that functional, biochemical, and cardiopulmonary status in patients with HF have significant improvements when treated with testosterone supplementation. Symptomatic improvements may be obtainable in hypogonadal patients with HF who receive supplemental testosterone. This review seeks to outline the cardiovascular and peripheral effects of testosterone supplementation in patients with chronic HF.


Subject(s)
Heart Failure/physiopathology , Hormone Replacement Therapy , Hypogonadism/drug therapy , Testosterone/therapeutic use , Drug Administration Routes , Drug Monitoring , Heart Failure/blood , Heart Failure/metabolism , Hemodynamics/drug effects , Hormone Replacement Therapy/adverse effects , Humans , Hypogonadism/blood , Hypogonadism/etiology , Male , Testosterone/administration & dosage , Testosterone/adverse effects , Testosterone/blood
5.
J Cardiovasc Pharmacol Ther ; 16(2): 140-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21097669

ABSTRACT

Heparin has been used in the catheterization laboratory to prevent ischemic complications of percutaneous coronary intervention (PCI). Bivalirudin, a direct thrombin inhibitor, is an anticoagulant that has several pharmacologic advantages over heparin, and it has been proposed that bivalirudin is superior to heparin in its ability to prevent bleeding complications of PCI. As such, there have been a variety of large prospective clinical trials comparing bivalirudin and heparin over the past 13 years. The results of these trials have prompted the general acceptance of bivalirudin as a safe alternative to heparin use during PCI, and bivalirudin has been given a class 1 recommendation by the American College of Cardiology/American Heart Association (ACC/AHA) guidelines for a variety of clinical indications. This article will review the data supporting the use of bivalirudin in the cardiac catheterization laboratory and describe several advantages of bivalirudin over traditional heparin use. We also include a discussion of the use of bivalirudin in conjunction with other medications that are frequently used in the catheterization laboratory. We end with an analysis of the economic differences between bivalirudin and heparin and the impact that financial factors may have on the choice of anticoagulant.


Subject(s)
Angioplasty, Balloon, Coronary/methods , Antithrombins/therapeutic use , Peptide Fragments/therapeutic use , Angioplasty, Balloon, Coronary/adverse effects , Anticoagulants/adverse effects , Anticoagulants/economics , Anticoagulants/therapeutic use , Antithrombins/adverse effects , Antithrombins/economics , Cardiac Catheterization/adverse effects , Cardiac Catheterization/methods , Drug Costs , Heparin/adverse effects , Heparin/economics , Heparin/therapeutic use , Hirudins/adverse effects , Hirudins/economics , Humans , Peptide Fragments/adverse effects , Peptide Fragments/economics , Practice Guidelines as Topic , Recombinant Proteins/adverse effects , Recombinant Proteins/economics , Recombinant Proteins/therapeutic use
6.
J Relig Health ; 50(4): 872-9, 2011 Dec.
Article in English | MEDLINE | ID: mdl-20191322

ABSTRACT

Deciding who should receive maximal technological treatment options and who should not represents an ethical, moral, psychological and medico-legal challenge for health care providers. Especially in patients with chronic heart failure, the ethical and medico-legal issues associated with providing maximal possible care or withholding the same are coming to the forefront. Procedures, such as cardiac transplantation, have strict criteria for adequate candidacy. These criteria for subsequent listing are based on clinical outcome data but also reflect the reality of organ shortage. Lack of compliance and non-adherence to lifestyle changes represent relative contraindications to heart transplant candidacy. Mechanical circulatory support therapy using ventricular assist devices is becoming a more prominent therapeutic option for patients with end-stage heart failure who are not candidates for transplantation, which also requires strict criteria to enable beneficial outcome for the patient. Physicians need to critically reflect that in many cases, the patient's best interest might not always mean pursuing maximal technological options available. This article reflects on the multitude of critical issues that health care providers have to face while caring for patients with end-stage heart failure.


Subject(s)
Cardiopulmonary Resuscitation/ethics , Heart Failure/therapy , Heart Transplantation/ethics , Heart-Assist Devices/ethics , Sick Role/ethics , Cardiopulmonary Resuscitation/psychology , Disease Management , Humans , Patient Selection , Quality of Life
7.
J Cardiovasc Pharmacol Ther ; 15(3): 231-43, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20595625

ABSTRACT

Recent advances in heart failure therapy include a variety of mechanical and device-based technologies that target structural aspects of heart failure that cannot be treated with drug therapy alone; these newer therapies can collectively be described as interventional heart failure therapy. This article is the second in a 2-part series reviewing interventional heart failure therapy. Interventions included in this discussion include those indicated for the treatment of end-stage refractory heart failure, including interventional medical therapy, interventional treatment of valvular disease, mechanical assist devices, and heart transplantation. Also included is a review of the currently available catheter-based pumps, which are intended to provide temporary support in patients with acute hemodynamic compromise. The use of cellular or stem cell therapy for the treatment of heart failure is an emerging interventional therapy and data supporting its use for the treatment heart failure will also be presented, as will a discussion of the role of palliative care and self-care in heart failure therapy.


Subject(s)
Heart Failure/therapy , Heart Valve Diseases/therapy , Cardiotonic Agents/therapeutic use , Heart Failure/drug therapy , Heart Failure/surgery , Heart Transplantation , Heart Valve Diseases/drug therapy , Heart Valve Diseases/surgery , Heart-Assist Devices , Humans , Palliative Care , Self Care , Stem Cell Transplantation
8.
J Cardiovasc Med (Hagerstown) ; 11(12): 919-27, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20671567

ABSTRACT

Heart failure is a chronic and debilitating disease responsible for high cardiac morbidity and mortality in the world and is associated with over 290 000 deaths in the United States each year. This article reviews palliative care and self-care, which are critical components of heart failure management that are inadequately defined in the current American College of Cardiology/American Heart Association Guidelines for the Diagnosis and Management of Heart Failure. Palliative care describes a multidisciplinary approach to the treatment of heart failure therapy that addresses both the symptomatic and psychosocial aspects of the disease. Self-care aims to maintain disease stability and prevent clinical decline through a variety of patient-based behavioral and lifestyle modifications.


Subject(s)
Heart Failure/therapy , Palliative Care , Self Care , Health Behavior , Health Knowledge, Attitudes, Practice , Heart Failure/psychology , Humans , Palliative Care/standards , Patient Care Team/standards , Patient Education as Topic , Practice Guidelines as Topic , Risk Reduction Behavior , Self Care/standards , Treatment Outcome
9.
Vasc Health Risk Manag ; 6: 273-80, 2010 May 06.
Article in English | MEDLINE | ID: mdl-20479949

ABSTRACT

Pulmonary hypertension (PH) is found in a vast array of diseases, with a minority representing pulmonary arterial hypertension (PAH). Idiopathic PAH or PAH in association with other disorders has been associated with poor survival, poor exercise tolerance, progressive symptoms of dyspnea, and decreased quality of life. Left untreated, patients with PAH typically have a progressive decline in function with high morbidity ultimately leading to death. Advances in medical therapy for PAH over the past decade have made significant inroads into improved function, quality of life, and even survival in this patient population. Three classes of pulmonary artery-specific vasodilators are currently available in the United States. They include prostanoids, endothelin receptor antagonists, and phosphodiesterase type 5 (PDE5) inhibitors. In May 2009, the FDA approved tadalafil, the first once-daily PDE5 inhibitor for PAH. This review will outline the currently available data on tadalafil and its effects in patients with PAH.


Subject(s)
Antihypertensive Agents/administration & dosage , Carbolines/administration & dosage , Hypertension, Pulmonary/drug therapy , Phosphodiesterase 5 Inhibitors , Phosphodiesterase Inhibitors/administration & dosage , Vasodilator Agents/administration & dosage , Administration, Oral , Antihypertensive Agents/adverse effects , Blood Pressure/drug effects , Carbolines/adverse effects , Cyclic Nucleotide Phosphodiesterases, Type 5/metabolism , Drug Administration Schedule , Humans , Hypertension, Pulmonary/enzymology , Hypertension, Pulmonary/physiopathology , Phosphodiesterase Inhibitors/adverse effects , Tadalafil , Treatment Outcome , Vasodilator Agents/adverse effects
10.
J Cardiovasc Pharmacol Ther ; 15(2): 102-11, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20435990

ABSTRACT

Congestive heart failure is a chronic and debilitating disease responsible for high cardiac morbidity and mortality in the world and is associated with more than 290 000 deaths in the United States each year. Recent advances in heart failure therapy target many of the mechanical and structural aspects of heart failure that are not addressed by drug-based therapies; these include abnormalities in electrical conduction, coronary artery or valvular architecture, and in ventricular size and shape. To target these abnormalities, newer therapies have largely been mechanical and device-based in nature and can be collectively described as interventional therapy. Interventional therapy includes the use of interventional medical therapy, electrical-based devices to augment ventricular function, catheterization-based devices for the treatment of underlying coronary artery disease and valvular disease, machines for the removal of excess fluid, mechanical pumps to assist the ventricles, surgical techniques aimed at reshaping the ventricles, the use of tissue therapies such as stem cell transplantation or complete heart transplant, palliative care, and self-care. This article is the first in a 2-part series that will review interventional heart failure therapy and present the most recent data supporting its use.


Subject(s)
Coronary Artery Disease/therapy , Heart Failure/therapy , Cardiac Catheterization/methods , Cardiac Surgical Procedures/methods , Heart Conduction System/physiopathology , Heart Failure/physiopathology , Heart Valves/physiopathology , Heart Ventricles/physiopathology , Heart-Assist Devices , Humans , United States , Vagus Nerve Stimulation/methods
SELECTION OF CITATIONS
SEARCH DETAIL